On September 16, GemPharmatech was honored to host a scientific seminar at Shonan Health Innovation Park (Shonan iPark), one of Japan’s leading hubs for life sciences and drug discovery. As the country’s first pharma-led, open innovation ecosystem, Shonan iPark provides a vital platform for researchers and companies to collaborate and accelerate biomedical innovation. 

Our seminar, “Innovative Mouse Models and Comprehensive Preclinical Approaches for Advancing Translational Drug Development,” highlighted how cutting-edge mouse models and integrated preclinical services can address translational challenges in neuroscience, oncology, and autoimmunity. 

During this exclusive seminar, GemPharmatech scientific leaders presented their insights in several therapeutic research areas, including: 

• Neuroscience: 

  Dr. Rikki Feng explained that mechanism-driven mouse models accelerate the development of targeted therapies for neurological diseases and create stronger bridges between basic research and clinical application. 

• Oncology:

  Dr. Hongyan Sun demonstrated that mouse models replicating resistance mechanisms to antibody–drug conjugates and checkpoint blockade therapies provide critical insights for overcoming therapeutic resistance, while humanized systems capturing antigen expression and T-cell dynamics improve the evaluation of next-generation immuno-oncology drugs. 

• Autoimmunity:

  Dr. Wen Zeng discussed that the translation of B-cell targeted therapies from oncology into autoimmune indications presents unique challenges, and disease-specific models play an essential role in evaluating efficacy, safety, and clinical translatability. 

By partnering with Shonan iPark, GemPharmatech is committed to providing Japanese researchers with direct access to one of the world’s largest collections of genetically engineered mouse models — more than 25,000 strains — along with trusted preclinical services. In addition, GemPharmatech offers a wide range of efficacy studies, integrating model generation, phenotype validation, molecular analysis, and pharmacology studies. Our comprehensive approach enables researchers in Japan to reduce translational risk, generate clinically relevant data, and accelerate the delivery of new treatments to patients. 

This seminar was an important step toward building deeper collaborations with the Japanese scientific community. We look forward to continuing to work alongside researchers at Shonan iPark and beyond, advancing biomedical discovery together. 

For presentation materials or collaboration inquiries, please contact: globalservice@gempharmatech.com